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Background: This study was carried out to evaluate the eﬀects of vitamin D and probiotic co-supplementation on
mental health parameters and metabolic status in diabetic people with coronary heart disease (CHD).
Methods: This randomized, double-blind, placebo-controlled trial was carried out among 60 diabetic people with
CHD, aged 45–85 years old. Subjects were randomly allocated into two groups to receive either 50,000 IU vi-
tamin D every 2 weeks plus 8× 109 CFU/g probiotic of Lactocare Zisttakhmir Co (n=30) or placebo (n=30)
for 12 weeks. Fasting blood samples were obtained at baseline and after the 12-week intervention to determine
metabolic proﬁles.
Results: After the 12-week intervention, compared with the placebo, vitamin D and probiotic
co-supplementation resulted in signiﬁcant improvements in beck depression inventory total score
(−2.8 ± 3.8 vs. −0.9 ± 2.1, P=0.01), beck anxiety inventory scores (−2.1 ± 2.3 vs. −0.8 ± 1.4,
P=0.009) and general health questionnaire scores (−3.9 ± 4.1 vs. −1.1 ± 3.4, P= 0.005). Compared with
the placebo, vitamin D and probiotic co-supplementation resulted in signiﬁcant reductions in serum insulin
levels (−2.8 ± 3.8 vs. +0.2 ± 4.9 μIU/mL, P= 0.009), homeostasis model of assessment-estimated insulin
resistance (−1.0 ± 1.6 vs. −0.1 ± 1.5, P= 0.02), and a signiﬁcant increase in serum 25-OH-vitamin D
(+11.8 ± 5.9 vs. +0.1 ± 1.4 ng/mL, P < 0.001), the quantitative insulin sensitivity check index
(+0.03 ± 0.04 vs. −0.001 ± 0.01, P= 0.003) and serum HDL-cholesterol levels (+2.3 ± 3.5 vs.
−0.5 ± 3.8mg/dL, P=0.004). In addition, changes in serum high sensitivity C-reactive protein (hs-CRP)
(−950.0 ± 1811.2 vs. +260.5 ± 2298.2 ng/mL, P=0.02), plasma nitric oxide (NO) (+1.7 ± 4.0 vs.
−1.4 ± 6.7 μmol/L, P=0.03) and plasma total antioxidant capacity (TAC) (+12.6 ± 41.6 vs.
−116.9 ± 324.2mmol/L, P= 0.03) in the supplemented group were signiﬁcantly diﬀerent from the changes in
these indicators in the placebo group.
Conclusions: Overall, vitamin D and probiotic co-supplementation after 12weeks among diabetic people with
CHD had beneﬁcial eﬀects on mental health parameters, serum hs-CRP, plasma NO, TAC, glycemic control and
HDL-cholesterol levels.
Clinical trial registration number: http://www.irct.ir: IRCT2017073033941N4.
1. Introduction
Previous studies suggest that type 2 diabetes mellitus (T2DM) and
coronary heart diseases (CHD) are comorbidities and the major risk
factors of mortality (Gaiz et al., 2017; Gress et al., 2000). CHD is re-
sponsible for> 80% of death in people with T2DM (Rathmann and
Giani, 2004). Cognitive impairment, depression, and functional
disability are involved in the course history of the disease (Gregg et al.,
2002). Insulin resistance and hyperinsulinemia in people with T2DM
cause metabolic disorders; leading to decreased nitric oxide (NO)
synthesis in blood vessel walls (Keymel et al., 2011). Furthermore, in-
ﬂammation and oxidative stress play important roles in the develop-
ment of T2DM and CHD (Chehaibi et al., 2016; Tatsch et al., 2015), and
the close relationship between increased inﬂammation and oxidative
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stress in both diseases is now well deﬁned.
Earlier, some studies have reported the beneﬁcial eﬀects of vitamin
D and probiotic in people with T2DM and CHD. We have previously
showed that vitamin D supplementation (50,000 IU/2week) for
6months to diabetic patients with CHD had beneﬁcial eﬀects on gly-
cemic status and high-sensitivity C-reactive protein (hs-CRP), NO,
glutathione (GSH), and malondialdehyde (MDA) levels, but did not
inﬂuence other metabolic proﬁles (Farrokhian et al., 2017). Vitamin D
supplementation (50,000 IU/week) for 10 weeks to people with non-
alcoholic fatty liver disease decreased insulin resistance and fasting
glucose (Foroughi et al., 2016). Also, in a meta-analysis study, probiotic
supplementation in patients with T2DM could improve fasting glucose,
HDL-cholesterol, but did not aﬀect other markers of glycemic control
and lipid proﬁles (Li et al., 2016). However, no beneﬁcial eﬀects on
cardiovascular risk were seen following the supplementation of
2000 IU/day vitamin D for 24 weeks to people T2DM (Ryu et al., 2014).
There is evidence that suggest the importance of vitamin D and pro-
biotic co-supplementation on metabolic proﬁles. In a study by Jones
et al. (2013), it was seen that circulating vitamin D in response to oral
probiotic supplementation had signiﬁcantly increased.
Given the antioxidant and anti-inﬂammatory eﬀects of vitamin D
and probiotic, we hypothesized that vitamin D and probiotic co-sup-
plementation might be beneﬁcial in diabetic people with CHD. The
present study was, therefore, conducted to evaluate the eﬀects of vi-
tamin D and probiotic co-supplementation on mental health parameters
and metabolic status in diabetic people with CHD.
2. Methods
2.1. Trial design and participants
This study was a 12-week randomized double-blinded placebo-
controlled clinical trial was registered with the website for registration
of clinical trials in Iran (http://www.irct.ir: IRCT2017073033941N4).
People with T2DM diagnosed based on the criteria of the American
Diabetes Association (Diagnosis and classiﬁcation of diabetes mellitus,
2014), aged 45–85 years with CHD diagnosed based on the American
Heart Association (Welles et al., 2014) with 2- and 3-vessel CHD were
included. The study was conducted from August 2017 and November
2017. Study protocol was approved by the research ethics committee of
Kashan University of Medical Sciences (KAUMS) and informed consent
was taken from all participants. Those taking vitamin D, probiotic and/
or synbiotic within the last 3 months, and patients with thyroid dis-
orders were not included in this study.
2.2. Study procedures
Firstly, all people were randomized into two groups to intake either
50,000 IU vitamin D3 every 2 weeks plus 8×109 CFU/g probiotic,
containing Lactobacillus acidophilus, Biﬁdobacterium biﬁdum,
Lactobacillus reuteri, and Lactobacillus fermentum (each 2×109)
(n=30) or placebo (n=30) for 12 weeks. In addition, all people were
matched according to age, BMI, gender and the dosage and type of
medications. Vitamin D, probiotic and its placebos (paraﬃn and starch,
respectively) were produced by Zahravi Pharmaceutical Company
(Tabriz, Iran), Lactocare Zisttakhmir Company (Tehran, Iran) and Barij
Essence Pharmaceutical Company (Kashan, Iran), respectively. They
were completely identical in terms of their appearance, color, shape,
size, smell and taste and packaging. Randomization process was con-
ducted using computer-generated random numbers by a trained staﬀ at
the clinic, blinded to both participants and researchers. Compliance was
evaluated by counting the remaining supplements and subtracting from
the number of supplements provided to the participants and the mea-
surement of serum 25-hydroxyvitamin D levels with the enzyme-linked
immunosorbent assay (ELISA) method. A 3-day food record was ob-
tained at week 1, 5, 9 and 12 of the intervention and macro- and micro-
nutrients intakes were determined using the Modiﬁed Nutritionist-4
software program (First Databank, San Bruno, CA) adapted for the
Iranian food pattern (Azar and Sarkisian, 1980).
2.3. Assessment of outcomes
Glycemic control was considered as the primary outcomes, and
parameters of mental health and other metabolic proﬁles were deﬁned
as the secondary outcomes. Ten milliliters fasting blood samples were
drown from antecubital vein at the beginning and after the 12-week
intervention at Kashan reference laboratory, Kashan, Iran. Blood was
collected in 2 separate tubes: 1) one without ethylenediaminete-
traacetic acid (EDTA) to separate the serum, in order to determine
serum insulin, lipid proﬁles and hs-CRP concentrations and 2) another
one containing EDTA to assess plasma NO and biomarkers of oxidative
stress. Blood samples were immediately centrifuged (Hettich D-78532,
Tuttlingen, Germany) at 3500 rpm for 10min to separate the serum,
and were then stored at −80 °C until being analyzed at the KAUMS
reference laboratory. Enzymatic kits (Pars Azmun, Tehran, Iran) were
used to evaluate fasting plasma glucose (FPG) and lipid proﬁles with
inter- and intra-assay coeﬃcient of variations (CVs)< 5%. Insulin va-
lues were assessed by the use of ELISA kit (DiaMetra, Milano, Italy)
with inter- and intra-assay CVs of 3.4 to 4.9%, respectively. The
homeostasis model of assessment-insulin resistance (HOMA-IR) and the
quantitative insulin sensitivity check index (QUICKI) were determined
according to the standard formula (Pisprasert et al., 2013). Hs-CRP
values were determined by an ELISA kit (LDN, Nordhorn, Germany)
with inter- and intra-assay CVs of lower than 7.0%. Plasma total anti-
oxidant capacity (TAC) by the method of Benzie and Strain (1996), GSH
using the method of Beutler and Gelbart (1985), MDA by the method of
spectrophotometric test (Janero, 1990), and NO levels using Griess
method (Tatsch et al., 2011) were determined with inter- and intra-
assay CVs of lower than 5%. Systolic (SBP) and diastolic blood pressure
(DBP) was determined via a sphygmomanometer (ALPK2, Zhejiang,
China).
2.4. Clinical assessment
Beck Depression Inventory (BDI) was assessed using a self-compiled
questionnaire (Beck et al., 1961). Anxiety evaluated by Beck Anxiety
Inventory (BAI) developed by Beck et al. (1988). The general health
questionnaire-28 (GHQ-28) comprises 28-item consisting of 4 subscales
(Goldberg and Hillier, 1979).
2.5. Statistical methods
The normality of study variables was determined using the
Kolmogorov-Smirnov test. Outcome log-transformation was used if
model residual has non-normal distribution (MDA, SBP and DBP). The
intention-to-treat (ITT) analysis was applied for all randomly allocated
subjects. Anthropometric measures as well as macro- and micro-nu-
trient dietary intakes were compared between the two groups, using
independent samples t-test. The eﬀects of vitamin D and probiotic co-
supplementation on mental health parameters and metabolic proﬁles
were assessed using repeated measures analysis of variance. The P-
value of< 0.05 was considered statistically signiﬁcant. All statistical
analyses in this study were conducted using the Statistical Package for
Social Science version 18 (SPSS Inc., Chicago, Illinois, USA).
3. Results
Four subjects in the supplements and placebo groups were dropped
out for personal reasons (Fig. 1). However, all 60 people were included
in the ﬁnal analysis based on the ITT principle. Overall, the compliance
rate was high, because of> 90% of capsules were consumed
throughout the study in both groups.
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Mean age, height, weight, BMI and METs at baseline and after the
12-week treatment were not statistically diﬀerent between treatment
and placebo groups (Table 1).
We observed no signiﬁcant changes in macro- and micronutrients
between the two groups (Data not shown).
Compared with the placebo, vitamin D and probiotic co-supple-
mentation led to signiﬁcant improvements in BDI score (−2.8 ± 3.8
vs. −0.9 ± 2.1, P= 0.01), BAI scores (−2.1 ± 2.3 vs. −0.8 ± 1.4,
P= 0.009) and GHQ scores (−3.9 ± 4.1 vs. −1.1 ± 3.4, P= .005)
(Table 2). Compared with the placebo, vitamin D and probiotic co-
supplementation resulted in a signiﬁcant reduction in insulin values
(−2.8 ± 3.8 vs. +0.2 ± 4.9 μIU/mL, P=0.009), HOMA-IR
(−1.0 ± 1.6 vs.−0.1 ± 1.5, P= 0.02), and a signiﬁcant elevation in
25-OH-vitamin D (+11.8 ± 5.9 vs. +0.1 ± 1.4 ng/mL, P < 0.001),
QUICKI (+0.03 ± 0.04 vs. −0.001 ± 0.01, P=0.003) and serum
HDL-cholesterol levels (+2.3 ± 3.5 vs. −0.5 ± 3.8mg/dL,
P= 0.004). In addition, changes in hs-CRP (−950.0 ± 1811.2 vs.
+260.5 ± 2298.2 ng/mL, P=0.02), plasma NO (+1.7 ± 4.0 vs.
−1.4 ± 6.7 μmol/L, P= 0.03) and plasma TAC (+12.6 ± 41.6 vs.
−116.9 ± 324.2 mmol/L, P=0.03) in the supplemented group were
signiﬁcantly diﬀerent from the placebo group.
4. Discussion
We found that vitamin D and probiotic co-supplementation for
12 weeks to diabetic people with CHD had beneﬁcial eﬀects on mental
health parameters, glycemic control, HDL-cholesterol levels, hs-CRP,
NO and TAC levels. To our knowledge, this research is the ﬁrst study
conducted to determine the eﬀects of vitamin D and probiotic co-sup-
plementation on mental health parameters and metabolic proﬁles
among diabetic people with CHD.
4.1. Eﬀect on clinical symptoms
We proved that vitamin D and probiotic co-supplementation for
12 weeks to diabetic people with CHD signiﬁcantly improved mental
health parameters. In agreement with our study, after the 9-week vi-
tamin D supplementation (50,000 IU/week) among adolescent girls,
there was a signiﬁcant reduction on mild, moderate, and severe de-
pression score (Bahrami et al., 2017). We have previously reported that
taking 50,000 IU/2week vitamin D supplement for 12 weeks by main-
tenance methadone treatment subjects had favorable eﬀects on
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Fig. 1. Summary of patient ﬂow diagram.
Table 1
General characteristics of study participants.
Placebo group
(n= 30)
Vitamin plus probiotic group
(n= 30)
Pa
Age (y) 67.3 ± 11.0 71.5 ± 10.9 0.13
Gender
Female 16 (53.3) 14 (46.7) 0.60b
Male 14 (46.7) 16 (53.3)
Height (m) 159.7 ± 9.4 156.1 ± 11.0 0.17
Weight at study baseline
(kg)
72.4 ± 15.5 70.1 ± 13.4 0.53
Weight at end-of-trial
(kg)
72.5 ± 15.4 70.0 ± 13.4 0.51
Body weight change
(kg)
0.1 ± 1.5 −0.1 ± 0.7 0.64
BMI at study baseline
(kg/m2)
28.2 ± 4.9 29.0 ± 6.2 0.59
BMI at end-of-trial (kg/
m2)
28.3 ± 4.8 29.0 ± 6.2 0.62
BMI change (kg/m2) 0.1 ± 0.6 −0.01 ± 0.3 0.69
MET-h/day at study
baseline
26.8 ± 1.9 27.1 ± 1.8 0.50
MET-h/day at end-of-
trial
26.9 ± 2.0 27.2 ± 2.0 0.48
MET-h/day change 0.1 ± 0.5 0.1 ± 0.8 0.80
Data are means ± SDs.
BMI, body mass index; METs, metabolic equivalents.
a Obtained from independent samples t-test.
b Obtained from Pearson Chi-square test.
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psychological symptoms (Ghaderi et al., 2017). In addition, probiotic
supplementation for 12 weeks to people with multiple sclerosis was
beneﬁt in improving parameters of mental health (Kouchaki et al.,
2017). However, high-dose VD3 supplementation (50,000 IU/week) for
52 weeks to dialysis population did not improve the depressive symp-
toms, but had a beneﬁcial eﬀect on vascular depression (Wang et al.,
2016). In a meta-analysis study, probiotic supplementation had an in-
signiﬁcant eﬀect on mood (Ng et al., 2017). Increased gene expression
of tyrosine hydroxylase and enhancement of the bioavailability of
multiple neurotransmitters like dopamine and noradrenalin by vitamin
D may improve mental health parameters (Humble, 2010; Khoraminya
et al., 2013). Furthermore, probiotic might improve symptoms of
mental health through elevated tryptophan concentrations and reduced
serotonin levels (Desbonnet et al., 2008). The synergism between the
immunomodulatory and anti-inﬂammatory eﬀects of both vitamin D
and probiotic might boost their eﬀect on clinical symptoms of psy-
chiatric illnesses.
4.2. Eﬀect on metabolic abnormalities
We found that 12-week vitamin D plus probiotic administration to
diabetic people with CHD was associated with signiﬁcant reductions in
insulin, HOMA-IR, and a signiﬁcant rise in QUICKI and serum HDL-
cholesterol levels, but unchanged FPG and other lipid proﬁles.
Mirhosseini et al. (2017) found that vitamin D supplementation, a
minimum dose of 4000 IU/day, signiﬁcantly decreased FPG, HbA1c,
and HOMA-IR, and improved insulin sensitivity in people with T2DM.
Consuming vitamin D by women with gestational diabetes mellitus
resulted in a signiﬁcant decrease in HOMA-IR, QUICKI, and LDL-cho-
lesterol concentrations, but did not useful for improving other meta-
bolic proﬁles (Akbari et al., 2017). In addition, another meta-analysis
study demonstrated that probiotic supplementation decreased HbA1c,
insulin levels and HOMA-IR in patients with T2DM, but did not aﬀect
lipid proﬁles (Yao et al., 2017). Probiotic supplementation also im-
proved lipid metabolism through decreasing total- and LDL-cholesterol
values, but unchanged other lipid proﬁles (Cho and Kim, 2015). Insulin
resistance results in peripheral arterial disorder, hypertension, and the
endothelial cell dysfunctions, thus increasing risk factors for stroke and
heart failure (Patel et al., 2016). Vitamin D intake plays a key role in the
regulation of cellular calcium signaling along with an indirect eﬀect on
regulating insulin secretion (Bergsten, 1995). Furthermore, vitamin D
may aﬀect C-peptide production (Marques et al., 2004), and suppress
renin-angiotensin activity (Takiishi et al., 2014). Probiotic intake may
have anti-diabetic eﬀects due to facilitating production of SCFA
(Belenguer et al., 2006). In addition, probiotic may improve insulin
sensitivity by increased anti-inﬂammatory factors production and de-
creased oxidative stress (Ma et al., 2004; Paszti-Gere et al., 2012).
4.3. Eﬀect on inﬂammation and oxidative stress
This research proved that compared with the placebo, taking vi-
tamin D plus probiotic for 12 weeks by diabetic people with CHD de-
creased hs-CRP, and increased NO and TAC levels, but unaltered GSH
and MDA levels. We have previously showed that vitamin D supple-
mentation.
(50,000 IU/2week) for 12 weeks to women with PCOS had bene-
ﬁcial eﬀects on hs-CRP and MDA levels, but did not aﬀect other para-
meters of inﬂammation and oxidative stress (Maktabi et al., 2017). In
addition, vitamin D3 intake (200,000 IU) signiﬁcantly decreased in-
ﬂammatory markers and increased TAC after 4 weeks in elderly subjects
(de Medeiros Cavalcante et al., 2015). Supporting our ﬁndings, the
consumption of 200 g/day yogurt containing probiotic (108 CFU/g
each) for 8 weeks in overweight people decreased inﬂammatory factors
(Zarrati et al., 2014). However, in a meta-analysis study, vitamin D
intake did aﬀect no signiﬁcant inﬂuence on inﬂammatory factors
(Jamka et al., 2016). Moreover, in a meta-analysis study conducted
among people with T2DM, probiotic use did not have a signiﬁcant ef-
fect on CRP levels (Kasinska and Drzewoski, 2015). T2DM is correlated
with the elevated biomarkers of inﬂammation and oxidative stress
(Styskal et al., 2012). The diﬀerent ﬁndings might be explained by
diﬀerent parameters like disease condition, vitamin D and probiotic
dose, and diﬀerent study designs. Less production of parathyroid hor-
mone (Struglia et al., 2015), decreasing reactive oxygen species and
pro-inﬂammatory factors by vitamin D (Jain and Micinski, 2013) might
Table 2
Mental health parameters, cardio-metabolic risk and biomarkers of oxidative stress at baseline and after the 12-week intervention in type 2 diabetic patients with coronary heart disease.
Placebo group (n=30) Vitamin D plus probiotic group (n= 30) P1
Baseline End-of-trial Change Baseline End-of-trial Change
Serum 25-OH-vitamin D (ng/mL) 13.8 ± 3.0 13.9 ± 3.4 0.1 ± 1.4 14.7 ± 2.9 26.5 ± 6.1 11.8 ± 5.9 <0.001
BDI score 21.5 ± 3.9 20.6 ± 3.7 −0.9 ± 2.1 23.2 ± 4.6 20.4 ± 3.4 −2.8 ± 3.8 0.01
BAI score 16.5 ± 4.0 15.7 ± 3.7 −0.8 ± 1.4 17.9 ± 4.7 15.8 ± 4.0 −2.1 ± 2.3 0.009
GHQ score 46.5 ± 7.0 45.4 ± 5.7 −1.1 ± 3.4 49.1 ± 7.7 45.1 ± 5.7 −3.9 ± 4.1 0.005
FPG (mg/dL) 126.8 ± 34.9 124.3 ± 34.8 −2.5 ± 17.9 121.3 ± 49.7 114.9 ± 46.6 −6.3 ± 26.5 0.51
Insulin (μIU/mL) 13.1 ± 7.8 13.3 ± 7.9 0.2 ± 4.9 13.7 ± 7.3 10.9 ± 7.4 −2.8 ± 3.8 0.009
HOMA-IR 4.0 ± 2.5 3.9 ± 2.5 −0.1 ± 1.5 4.2 ± 3.7 3.2 ± 2.6 −1.0 ± 1.6 0.02
QUICKI 0.32 ± 0.02 0.32 ± 0.02 −0.001 ± 0.01 0.32 ± 0.03 0.35 ± 0.06 0.03 ± 0.04 0.003
Triglycerides (mg/dL) 153.5 ± 65.4 153.6 ± 61.6 0.1 ± 17.7 149.2 ± 92.3 137.4 ± 61.5 −11.8 ± 69.7 0.37
VLDL-cholesterol (mg/dL) 30.7 ± 13.1 30.7 ± 12.3 0.01 ± 3.5 29.8 ± 18.5 27.5 ± 12.3 −2.4 ± 13.9 0.37
Total cholesterol (mg/dL) 146.7 ± 29.1 146.9 ± 33.9 0.3 ± 18.0 138.8 ± 41.7 144.2 ± 33.3 5.4 ± 30.5 0.43
LDL-cholesterol (mg/dL) 72.6 ± 18.7 73.3 ± 23.9 0.8 ± 16.4 68.1 ± 29.1 73.5 ± 28.2 5.4 ± 20.6 0.33
HDL-cholesterol (mg/dL) 43.4 ± 8.2 42.8 ± 7.4 −0.5 ± 3.8 40.9 ± 8.2 43.2 ± 8.2 2.3 ± 3.5 0.004
hs-CRP (ng/mL) 3430.9 ± 2939.3 3691.4 ± 3024.7 260.5 ± 2298.2 3410.0 ± 2384.9 2460.0 ± 2135.8 −950.0 ± 1811.2 0.02
NO (μmol/L) 37.7 ± 8.2 36.3 ± 8.7 −1.4 ± 6.7 38.5 ± 3.9 40.2 ± 3.3 1.7 ± 4.0 0.03
TAC (mmol/L) 1032.8 ± 367.7 915.8 ± 284.5 −116.9 ± 324.2 987.9 ± 91.7 1000.5 ± 91.4 12.6 ± 41.6 0.03
GSH (μmol/L) 510.6 ± 123.0 498.4 ± 158.5 −12.2 ± 122.5 686.4 ± 80.5 704.4 ± 142.7 18.0 ± 112.7 0.32
MDA (μmol/L) 3.3 ± 1.3 3.4 ± 1.0 0.1 ± 0.7 2.8 ± 0.2 2.7 ± 0.3 −0.1 ± 0.3 0.07
SBP (mmHg) 129.2 ± 8.5 128.2 ± 9.9 −1.0 ± 6.1 132.7 ± 7.9 132.0 ± 8.4 −0.7 ± 6.4 0.85
DBP (mmHg) 78.0 ± 8.3 76.7 ± 7.8 −1.3 ± 6.1 76.8 ± 7.2 76.1 ± 7.0 −0.7 ± 4.7 0.69
All values are means ± SDs.
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GHQ, General Health Questionnaire; GSH, total glutathione;
HOMA-IR, homeostasis model of assessment-estimated insulin resistance; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative
insulin sensitivity check index; SBP, systolic blood pressure; TAC, total antioxidant capacity.
1 P values represent the time× group interaction (computed by analysis of the one-way repeated measures ANOVA).
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describe its beneﬁcial eﬀects on inﬂammation and oxidative stress.
Furthermore, probiotic intake may useful in reducing inﬂammatory
factors through producing SCFA in the gut (Sadrzadeh-Yeganeh et al.,
2010) and the decreasing production of hydrogen peroxide radicals
(Komers and Anderson, 2003).
The current study had few limitations. We did not measure fecal
bacteria loads before and after probiotic intake, and characterization of
the microbiome at baseline, during and after therapy. In addition, we
did not evaluate the eﬀects of vitamin D and probiotic co-supple-
mentation on gene expression related to inﬂammation and insulin re-
sistance.
Overall, vitamin D and probiotic co-supplementation after 12 weeks
among diabetic people with CHD had beneﬁcial eﬀects on mental
health parameters, glycemic control, HDL-cholesterol levels, hs-CRP,
NO and TAC, but did not aﬀect other metabolic proﬁles and blood
pressures.
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